Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Cholicamideβ (compound 6), a self-assembling small molecule cancer vaccine adjuvant, forms low cytotoxicity virus-like particles and upon binding to peptide antigens, enhances dendritic cell-mediated antigen presentation and induces antigen-specific T-cell responses, with the ability to induce apoptosis and necrosis [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | Cholicamideβ (compound 6), a self-assembling small molecule cancer vaccine adjuvant, forms low cytotoxicity virus-like particles and upon binding to peptide antigens, enhances dendritic cell-mediated antigen presentation and induces antigen-specific T-cell responses, with the ability to induce apoptosis and necrosis [1]. |
In vitro | Cholicamideβ (compound 6) at concentrations of 4-16 μM induces apoptosis and necrosis in RAW264.7 cells over a period of 22 hours [1]. |
In vivo | Cholicamideβ (compound 6) administered at 100 μg/mouse with evaluation at 16 hours and 21 days post-injection, displayed low toxicity and elevated HA-specific IgG antibody titers [1] in C57BL/6 mice previously immunized with a split influenza vaccine. |
Molecular Weight | 879.34 |
Formula | C55H94N2O6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Cholicamideβ Apoptosis Necroptosis inhibitor inhibit